C-6MLLFountain Therapeutics
small molecules, aging biology, in vitro and in vivo screening
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-6MLL
C-6MLLC-6MLLsmall molecules, aging biology, in vitro and in vivo screening
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Fountain Therapeutics small molecules, aging biology, in vitro and in vivo screening
Fountain Therapeutics develops therapies for diseases and conditions caused by aging. Its lead programs target skin atrophy and age-associated lean tissue and muscle atrophy. The company describes a topical combination of FTX002600 and FTX003059 for skin atrophy and FTX008762 as a small molecule modulator intended to preserve lean tissue and muscle mass.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Fountain Therapeutics — Early mechanism · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic